Clinical activity of mitogen-activated protein kinase inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers Review
| Authors: | Dankner, M.; Rousselle, E.; Petrecca, S.; Fabi, F.; Nowakowski, A.; Lazaratos, A. M.; Vincent Rajadurai, C.; Stein, A. J. B.; Bian, D.; Tai, P.; Belaiche, A.; Li, M.; Quaiattini, A.; Normanno, N.; Arcila, M.; Elkrief, A.; Johnson, D. B.; Ladanyi, M.; Rose, A. A. N. |
| Review Title: | Clinical activity of mitogen-activated protein kinase inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers |
| Abstract: | PURPOSE MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy of mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) for MAP2K1-mutant tumors is not well defined. We sought to characterize the genomic and clinical landscape of MAP2K1 mutant tumors to evaluate the relationship between MAP2K1 mutation class and clinical activity of MAPKi. METHODS We interrogated American Association for Cancer Research (AACR) GENIE (v13) to analyze solid tumors with MAP2K1 mutations. We performed a systematic review and meta-analysis of published reports of patients with MAP2K1-mutant cancers treated with MAPKi according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary end point was progression-free survival (PFS), and secondary end points were overall treatment response rate (ORR), duration of response (DOR), and overall survival. RESULTS In the AACR GENIE data set, class 2 MAP2K1 mutations (63%) were more prevalent than class 1 (24%) and class 3 (13%) mutations (P < .0001). Co-occurring MAPK pathway-activating mutations were more likely to occur in class 1 versus class 2 or 3 MAP2K1-mutant tumors (P < .0001). Our systematic meta-analysis of the literature identified 46 patients with MAP2K1-mutant tumors who received MAPKi. In these patients, ORR was 28% and median PFS was 3.9 months. ORR did not differ according to MAP2K1 mutation class or cancer type. However, patients with class 2 mutations experienced longer PFS (5.0 months) and DOR (23.8 months) compared with patients with class 1, 3, or unclassified MAP2K1 mutations (PFS 3.5 months, P 5 .04; DOR 4.2 months, P 5 .02). CONCLUSION Patients with class 2 MAP2K1 mutations represent a novel subgroup that may derive benefit from MAPKi. Prospective clinical studies with novel MAPKi regimens are warranted in these patients. © 2025 by American Society of Clinical Oncology. |
| Keywords: | signal transduction; mitogen activated protein kinase; cancer survival; treatment response; aged; primary tumor; gene mutation; overall survival; review; solid tumor; cancer patient; quality control; metastasis; progression free survival; mitogen activated protein kinase inhibitor; lung cancer; phosphorylation; systematic review; genomics; meta analysis; mitogen activated protein kinase kinase inhibitor; human; male; female |
| Journal Title: | JCO Precision Oncology |
| Volume: | 9 |
| ISSN: | 2473-4284 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| Start Page: | e2400199 |
| Language: | English |
| DOI: | 10.1200/po.24.00199 |
| PUBMED: | 39869838 |
| PROVIDER: | scopus |
| PMCID: | PMC11784909 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work